1. Search Result
Search Result
Results for "

CD40/CD40L

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

12

Inhibitory Antibodies

36

Recombinant Proteins

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99315

    BG 9588; Anti-Human CD40L Recombinant Antibody

    TNF Receptor Inflammation/Immunology
    Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research .
    Ruplizumab
  • HY-122663A

    TNF Receptor Apoptosis Metabolic Disease
    BIO8898 is a potent CD40-CD154 inhibitor. BIO8898 inhibits soluble CD40L binding to CD40-Ig with an IC50 value of 25 µM. BIO8898 inhibits CD40L-induced apoptosis .
    BIO8898
  • HY-P99321

    BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody

    TNF Receptor Inflammation/Immunology Cancer
    Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
    Teneliximab
  • HY-P99625

    SAR441344; INX-021

    TNF Receptor Inflammation/Immunology
    Frexalimab (SAR441344; INX-021) is a monoclonal antibody targeting the CD40 ligand (CD40L). Frexalimab has the potential for multiple sclerosis research .
    Frexalimab
  • HY-154821

    TNF Receptor Inflammation/Immunology
    DRI-C21041 is a CD40/CD40L interaction inhibitor, with an IC50 of 0.31 μM. DRI-C21041 inhibits the immune response induced by alloantigen .
    DRI-C21041
  • HY-154821A

    TNF Receptor Inflammation/Immunology
    DRI-C21041 DIEA is a CD40/CD40L interaction inhibitor, with an IC50 of 0.31 μM. DRI-C21041 DIEA inhibits the immune response induced by alloantigen .
    DRI-C21041 (DIEA)
  • HY-P99167

    HCD122

    TNF Receptor Cancer
    Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
    Lucatumumab
  • HY-154822

    TNF Receptor Inflammation/Immunology
    DRI-C25441 is a potent blocker of CD40 and CD40L interaction, with an IC50 of 0.36 μM. DRI-C25441 can inhibit the immune response induced by alloantigen .
    DRI-C25441
  • HY-120323
    DRI-C21045
    1 Publications Verification

    TNF Receptor Inflammation/Immunology
    DRI-C21045 (compound 10) is a potent and selective inhibitor of the CD40-CD40L costimulatory protein-protein interaction (PPI) with an IC50 of 0.17 µM. DRI-C21045 shows concentration-dependent inhibition of the activation of NF-κB and B cell proliferation all induced by CD40L with IC50s of 17.1 µM and 4.5 µM, respectively .
    DRI-C21045
  • HY-P99325

    IDEC-131; Anti-Human CD40 ligand Recombinant Antibody

    TNF Receptor Inflammation/Immunology
    Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .
    Toralizumab
  • HY-16668

    Tyrphostin 1; AG9

    Interleukin Related Inflammation/Immunology
    Tyrphostin A1(AG9) inhibits CD40L-stimulated IL-12 production in macrophage cultures and antigen-induced generation of Th1 cells.
    Tyrphostin A1
  • HY-P99701

    BMS-986004

    TNF Receptor Inflammation/Immunology
    Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time .
    Letolizumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: